Skip to main content

Block, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

XYZ$85.58-3.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months EndedSeptember 30,
20252024
Cash flows from operating activities:
Net income$1,188,654$941,828
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization273,464287,249
Amortization of discounts and premiums and other non-cash adjustments(834,950)(824,219)
Non-cash lease expense42,54555,480
Share-based compensation921,957955,845
Loss (gain) on revaluation of equity investments(172,582)470
Remeasurement gain on bitcoin investment(178,402)(168,576)
Transaction, loan, and consumer receivable losses827,234549,603
Change in deferred income taxes182,7565,368
Purchases and originations of loans originally classified as held for sale(12,394,452)(10,887,619)
Proceeds from repayments of loans originally classified as held for sale12,457,57510,419,823
Changes in operating assets and liabilities:
Settlements receivable(291,388)1,577,463
Customers payable313,061(1,319,654)
Other assets and liabilities(376,758)100,489
Net cash provided by operating activities1,958,7141,693,550
Cash flows from investing activities:
Purchases of marketable debt securities(481,088)(1,035,477)
Proceeds from maturities of marketable debt securities423,312790,748
Proceeds from sale of marketable debt securities392,218436,912
Payments for originations of consumer receivables(22,553,302)(20,197,450)
Proceeds from principal repayments and sales of consumer receivables23,721,27521,142,547
Purchases and originations of loans originally classified as held for investment(7,643,830)—
Proceeds from repayments of loans originally classified as held for investment5,629,369—
Purchases of property and equipment(113,838)(126,954)
Purchases of other investments(45,930)(37,218)
Net cash provided by (used in) investing activities(671,814)973,108

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Continued

Nine Months EndedSeptember 30,
20252024
Cash flows from financing activities:
Proceeds from issuance of senior notes2,200,0002,000,000
Payments of debt issuance costs from issuance of senior notes(28,346)(26,619)
Payments to redeem convertible notes(1,000,624)—
Proceeds from warehouse facilities borrowings448,530406,359
Repayments of warehouse facilities borrowings(1,456,869)(1,054,091)
Proceeds from the exercise of stock options and purchases under the employee stock purchase plan58,24788,053
Net increase in interest-bearing deposits81,17673,687
Repurchases of common stock(1,540,529)(987,179)
Other financing activities(35,330)(18,473)
Change in customer funds, restricted from use in the Company's operations620,844763,355
Net cash provided by (used in) financing activities(652,901)1,245,092
Effect of foreign exchange rate on cash and cash equivalents80,51513,600
Net increase in cash, cash equivalents, restricted cash, and customer funds714,5143,925,350
Cash, cash equivalents, restricted cash, and customer funds, beginning of the period13,230,5129,009,087
Cash, cash equivalents, restricted cash, and customer funds, end of the period$13,945,026$12,934,437
Reconciliation of cash, cash equivalents, restricted cash, and customer funds:
Cash and cash equivalents$8,335,934$8,299,804
Short-term restricted cash731,590630,933
Long-term restricted cash73,78669,915
Customer funds cash and cash equivalents4,803,7163,933,785
Total$13,945,026$12,934,437
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.